Synthesis and biological evaluation of a novel β-D-2′-deoxy-2′-α-fluoro-2′-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection

Ertong Li, Yafeng Wang, Wenquan Yu, Zhigang Lv, Youmei Peng, Bingjie Liu, Shiliang Li, Wenzhe Ho, Qingduan Wang, Honglin Li, Junbiao Chang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

A novel β-D-2′-deoxy-2′-α-fluoro-2′-β-C-(fluoromethyl)uridine phosphoramidate prodrug (1) has been synthesized. This compound exhibits submicromolar-level antiviral activity in vitro against HCV genotypes 1b, 1a, 2a, and S282T replicons (EC50 = 0.18–1.13 μM) with low cytotoxicity (CC50 > 1000 μM). Administered orally, prodrug 1 is well tolerated at doses of up to 4 g/kg in mice, and produces a high level of the corresponding triphosphate in rat liver.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalEuropean Journal of Medicinal Chemistry
Volume143
DOIs
StatePublished - 1 Jan 2018
Externally publishedYes

Keywords

  • 2′-α-fluoro-2′-β-C-(fluoromethyl)uridine
  • Anti-HCV
  • Phosphoramidate prodrug
  • Triphosphate

Fingerprint

Dive into the research topics of 'Synthesis and biological evaluation of a novel β-D-2′-deoxy-2′-α-fluoro-2′-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection'. Together they form a unique fingerprint.

Cite this